U.S. Retail Pharmacy De-identified Health Data Market Size, Share & Trends Analysis Report By Dataset Type (DSCSA Data, Market Basket Data, Inventory Data, Prior Authorization Data), And Segment Forecasts, 2025 - 2030

Table of Content

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation & Scope
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Objectives
  • 1.2.1 Objective - 1
  • 1.2.2 Objective - 2
• 1.3 Segment Definitions
  • 1.3.1 DATASET TYPE
• 1.4 Research Methodology
  • 1.4.1 DSCSA (DRUG Supply Chain Security Act): Research Scope And Assumption
    • 1.4.1.1 Volume Estimation: DSCSA De-identified Data
    • 1.4.1.2 CAGR Calculation (2025-2030)
  • 1.4.2 Prior Authorization: Research Scope And Assumption
    • 1.4.2.1 Volume Estimation: Prior Authorization Data
    • 1.4.2.2 CAGR Calculation (2025-2030)
  • 1.4.3 Market Basket Data: Research Scope And Assumption
    • 1.4.3.1 Volume Estimation: Market Basket Data
    • 1.4.3.2 CAGR Calculation (2025-2030)
  • 1.4.4 Episodic Data / Pharmacy Rx Claims Data: Research Scope And Assumption
  • 1.4.5 Inventory Data: Research Scope And Assumption
    • 1.4.5.1 Market Share and Assumption
  • 1.4.6 Information Procurement
    • 1.4.6.1 Purchased database
    • 1.4.6.2 GVR'S internal database
    • 1.4.6.3 Primary research
      • 1.4.6.3.1 Details of the primary research
• 1.5 Information or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation & Validation
• 1.7 List of Secondary Sources
• 1.8 List of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Dataset Type - Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Industry Outlook - Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Global Market Outlook
• 3.2 Market Dynamics
  • 3.2.1 Outlook Of Key Drivers And Related Insights By Dataset Type
  • 3.2.2 Market Driver Analysis
    • 3.2.2.1 Increasing demand for real-world evidence (RWE) and real-world data (RWD)
    • 3.2.2.2 Favorable regulatory support for drug supply chain transparency (DSCSA Compliance)
    • 3.2.2.3 Growth of value-based care and outcome-based reimbursement models
  • 3.2.3 Market Restraint Analysis
    • 3.2.3.1 Stringent Privacy regulations and legal risk exposure
    • 3.2.3.2 Lack of data quality and data standardization
  • 3.2.4 Market Opportunity Analysis
    • 3.2.4.1 Integration with digital health, AI, and analytics platforms
  • 3.2.5 Market Challenge Analysis
    • 3.2.5.1 Ethical concerns and public distrust in data commercialization
• 3.3 Buyer Analysis
• 3.4 Regulatory Trends
• 3.5 U.S. Retail Pharmacy de-identified health data market (Specific to the Five Datasets - Retail Pharmacy as Seller): By Dataset Type Level Pricing Model details
  • 3.5.1 Drug Supply Chain Security Data (Dscsa): (Type 1 Segment) Overall Level Pricing Model Structure And Related Analysis
    • 3.5.1.1 Pricing Model Overview
      • 3.5.1.1.1 Model 1: Compliance-Tiered Licensing (Most Common)
      • 3.5.1.1.2 Model 2: Subscription-Based Access to Serialized Data Streams
      • 3.5.1.1.3 Model 3: Project-based or On-demand Query Models
    • 3.5.1.2 Price Range Analysis
      • 3.5.1.2.1 Retail Pharmacies as Sellers Example: CVS Health (ExtraCare Insights Platform)
      • 3.5.1.2.2 Retail Pharmacies as Sellers Example: Walgreens
  • 3.5.2 Market Basket Data: (Type 1 Segment) Overall Level Pricing Model Structure And Related Analysis
    • 3.5.2.1 Pricing Model Overview
      • 3.5.2.1.1 Model 1: Tiered Pricing Model (Most Common) (By Data Volume and Granularity)
      • 3.5.2.1.2 Model 2: Subscription-Based Access
      • 3.5.2.1.3 Model 3: Pay-per-Use or Custom Reports
    • 3.5.2.2 Price Range Analysis
      • 3.5.2.2.1 Retail Pharmacies as Sellers Example: CVS Health (ExtraCare Insights Platform)
      • 3.5.2.2.2 Retail Pharmacies as Sellers Example: Walgreens (Retail Analytics + Loyalty Program Data)
      • 3.5.2.2.3 Retail Pharmacies as Sellers Example: Rite Aid (Retail Pharmacy Analytics)
  • 3.5.3 Inventory Data: (Type 1 Segment) Overall Level Pricing Model Structure And Related Analysis
    • 3.5.3.1 Pricing Model Overview
      • 3.5.3.1.1 Model 1: Tiered Pricing Model (By Data Freshness and Geographic Depth)
      • 3.5.3.1.2 Model 2: Subscription-Based Access Data Feeds
      • 3.5.3.1.3 Model 3: Pay-per-Use or Targeted Alert Modules
    • 3.5.3.2 Price Range Analysis
      • 3.5.3.2.1 Retail Pharmacies as Sellers Example: CVS Health
      • 3.5.3.2.2 Retail Pharmacies as Sellers Example: Walgreens Boots Alliance
  • 3.5.4 Prior Authorization Data: (Type 1 Segment) Overall Level Pricing Model Structure And Related Analysis
    • 3.5.4.1 Pricing Model Overview
      • 3.5.4.1.1 Model 1: Event-based Data Feed Pricing (Most Common)
      • 3.5.4.1.2 Model 2: Subscription + Dashboard Access
      • 3.5.4.1.3 Model 3: Formulary Access Strategy Packages
    • 3.5.4.2 Price Range Analysis
      • 3.5.4.2.1 Retail Pharmacies as Sellers Example: CVS Health (Caremark (PBM arm) and MinuteClinic)
      • 3.5.4.2.2 Retail Pharmacies as Sellers Example: Walgreens
  • 3.5.5 Episodic Data / Pharmacy Rx Claims Data: (Type 1 Segment) Overall Level Pricing Model Structure And Related Analysis
    • 3.5.5.1 Pricing Model Overview
      • 3.5.5.1.1 Model 1: De-Identified Episodic Journey Files (Static Delivery)
      • 3.5.5.1.2 Model 2: Subscription-Based +Dashboard Or API
      • 3.5.5.1.3 Model 3: Custom Value-Based Care Packages
    • 3.5.5.2 Price Range Analysis
      • 3.5.5.2.1 Retail Pharmacies as Sellers Example: CVS Health MinuteClinic and HealthHUBs
      • 3.5.5.2.2 Retail Pharmacies as Sellers Example: Walgreens Health Corners
• 3.6 Industry Analysis Tools
  • 3.6.1 Porter's Five Forces Analysis
  • 3.6.2 Pestle Analysis
• 3.7 Retail-Pharmacy Specific Trends
• 3.8 Technological Advancements
• 3.9 COVID-19 Impact Analysis

Chapter 4 U.S. Retail Pharmacy de-identified health data market (Specific to the Five Datasets - Retail Pharmacy as Seller): Dataset Type Estimates & Trend Analysis

• 4.1 Segment Dashboard
• 4.2 U.S. Retail Pharmacy De-identified Health Data Market (Specific to the Five Datasets - Retail Pharmacy as Seller): Dataset Type Analysis, 2024 & 2030 (USD Million)
• 4.3 Retail Pharmacy- Enabled De-Identified Health Datasets: Feature Expectations and Provider Reference Practices (By Dataset Type)
  • 4.3.1 Data Integrity
  • 4.3.2 Data Recency & Update Frequency
  • 4.3.3 Data Breadth & Depth
  • 4.3.4 Data Usability
  • 4.3.5 Data Longitudinality
  • 4.3.6 Value Added Services
• 4.4 Retail Pharmacies as Data Sellers: Score Matrix
• 4.5 Drug Supply Chain Security Data (DSCSA) Market: (Type 1 segment)
  • 4.5.1 Drug Supply Chain Security Data (Dscsa) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2 DSCSA Data - Market Expectations By Buyer Type: (Type 2 Segment)
    • 4.5.2.1 Pharmaceutical Manufacturers Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.2.2 Drug Distributors Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.2.3 Regulatory Tech Vendors (e.g., TraceLink, LSPedia) Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.2.4 Healthcare SaaS Vendors Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.2.5 Others (Federal Agencies e.g., FDA, etc.) Market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6 Market Basket Data Market: (Type 1 segment)
  • 4.6.1 Market Basket Data Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2 Market Basket Data -Market Expectations By Buyer Type: (Type 2 Segment)
    • 4.6.2.1 CPG & Pharma Brands Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.6.2.2 Marketing & AdTech Firms Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.6.2.3 Health Insurers & PBMs Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.6.2.4 Retail Analytics Platforms Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.6.2.5 Others (Data Aggregators (e.g., NielsenIQ, IRI), etc.)) Market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.7 Inventory Data Market: (Type 1 segment)
  • 4.7.1 Inventory Data Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.7.2 Inventory Data - Market Expectations By Buyer Type: (Type 2 Segment)
    • 4.7.2.1 Pharma Manufacturers Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.7.2.2 Distributors/Wholesalers Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.7.2.3 AI/ML Inventory Optimization Vendors Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.7.2.4 Others (Clinical Supply Vendors, etc.) Market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.8 Prior Authorization Data Market: (Type 1 segment)
  • 4.8.1 Prior Authorization Data Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.8.2 Prior Authorization Data - Market Expectations By Buyer Type: (Type 2 Segment)
    • 4.8.2.1 Payers & PBMs Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.8.2.2 Pharma Market Access Teams Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.8.2.3 Health IT Providers Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.8.2.4 Consulting & Policy Firms Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.8.2.5 Others (Advocacy Groups, etc.) Market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.9 Episodic / Pharmacy Rx Claims Data Market: (Type 1 segment)
  • 4.9.1 Episodic / Pharmacy Rx Claims Data Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.9.2 Episodic / Pharmacy Rx Claims Data - Market Expectations By Buyer Type: (Type 2 Segment)
    • 4.9.2.1 Value-based Payers & ACOs Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.9.2.2 Pharma Outcomes Teams Market Access Teams Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.9.2.3 Real-world Evidence Vendors Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.9.2.4 CMS & Government Organizations Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.9.2.5 Others (AI/ML Healthtech Firms, etc.) Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Competitive Landscape

• 5.1 Participants' Overview
• 5.2 Financial Performance
  • 5.2.1 Public Companies
  • 5.2.2 Private Companies
• 5.3 Competitor Comparison Analysis & Benchmarking
  • 5.3.1 CVS HEALTH
    • 5.3.1.1 CVS Health- Estimated Pricing Models by Dataset Type
  • 5.3.2 WALMART
    • 5.3.2.1 Walmart - Estimated Pricing Models by Dataset Type
  • 5.3.3 WALGREENS
    • 5.3.3.1 Walgreens - Estimated Pricing Models by Dataset Type
    • 5.3.3.2 Walgreens Comparative Analysis Across Datasets (vs. Retail/Specialty Peers)
  • 5.3.4 THE KROGER CO.
    • 5.3.4.1 THE KROGER CO.- Estimated Pricing Models by Dataset Type
  • 5.3.5 ALBERTSON
    • 5.3.5.1 Albertson - Estimated Pricing Models by Dataset Type
  • 5.3.6 UNITEDHEALTH GROUP (OPTUM)
    • 5.3.6.1 UNITEDHEALTH GROUP (OPTUM) - Estimated Pricing Models by Dataset Type
  • 5.3.7 HUMANA
    • 5.3.7.1 HUMANA- Estimated Pricing Models by Dataset Type
  • 5.3.8 BRIGHTSPRING HEALTH SERVICES
    • 5.3.8.1 BrightSpring Health Services - Estimated Pricing Models by Dataset Type
  • 5.3.9 RITE AID CORP
    • 5.3.9.1 Rite Aid Corp - Estimated Pricing Models by Dataset Type
  • 5.3.10 H-E-B LP
    • 5.3.10.1 H-E-B LP - Estimated Pricing Models by Dataset Type
  • 5.3.11 COSTCO WHOLESALE CORPORATION
    • 5.3.11.1 COSTCO WHOLESALE CORPORATION- Estimated Pricing Models by Dataset Type
  • 5.3.12 CENTENE CORPORATION
    • 5.3.12.1 Centene Corporation- Estimated Pricing Models by Dataset Type
  • 5.3.13 KONINKLIJKE AHOLD DELHAIZE N.V.
    • 5.3.13.1 KONINKLIJKE AHOLD DELHAIZE N.V.- Estimated Pricing Models by Dataset Type
  • 5.3.14 AURORA HEALTH CARE (A PART OF ADVOCATE HEALTH)
    • 5.3.14.1 Aurora Health Care (a part of Advocate Health).- Estimated Pricing Models by Dataset Type
  • 5.3.15 BIG Y FOODS, INC.
    • 5.3.15.1 BIG Y FOODS, INC.- Estimated Pricing Models by Dataset Type
  • 5.3.16 BROOKSHIRE BROTHERS
    • 5.3.16.1 BROOKSHIRE BROTHERS - Estimated Pricing Models by Dataset Type
  • 5.3.17 WAKEFERN FOOD CORP.
    • 5.3.17.1 Wakefern Food Corp - Estimated Pricing Models by Dataset Type
  • 5.3.18 PUBLIX
    • 5.3.18.1 PUBLIX - Estimated Pricing Models by Dataset Type
  • 5.3.19 CUB (SUBSIDIARY OF UNITED NATURAL FOODS, INC.)
    • 5.3.19.1 Cub (subsidiary of United Natural Foods, Inc.) - Estimated Pricing Models by Dataset Type
• 5.4 Participant Categorization
• 5.5 Company Market Share Analysis, 2024 (%)
  • 5.5.1 Company Market Share Analysis, By Dscsa Dataset
  • 5.5.2 Company Market Share Analysis By Market Basket Data Dataset
  • 5.5.3 Company Market Share Analysis By Inventory Dataset
  • 5.5.4 Company Market Share Analysis By Episodic Data / Pharmacy Rx Claims Data
  • 5.5.5 Company Market Share Analysis By Prior Authorization
• 5.6 Strategy Mapping
  • 5.6.1 New Service Launch
  • 5.6.2 Partnerships And Collaboration
  • 5.6.3 Regional Expansion
  • 5.6.4 Others

List of Tables

• TABLE 1 List of secondary sources
• TABLE 2 List of abbreviations
• TABLE 3 Key commercial drivers, its impact, and insights
• TABLE 4 State-wise distribution of retail pharmacies in the U.S. (2024)
• TABLE 5 Buyer landscape at each dataset level

List of Figures

• FIG. 1 U.S. Retail Pharmacy de-identified health data market segmentation
• FIG. 2 Market research process
• FIG. 3 Data triangulation techniques
• FIG. 4 Primary research pattern
• FIG. 5 Market research approaches
• FIG. 6 Value-chain-based sizing & forecasting
• FIG. 7 Market formulation & validation
• FIG. 8 Market snapshot
• FIG. 9 Dataset Type -Segment snapshot
• FIG. 10 Competitive landscape snapshot
• FIG. 11 Global De-identified Health Data vs U.S. Retail Pharmacy de-identified health data market (Specific to the Five Datasets - Retail Pharmacy as Seller) outlook, 2024, USD Billion
• FIG. 12 U.S. Retail Pharmacy de-identified health data market dynamics
• FIG. 13 U.S. Retail Pharmacy de-identified health data market : Porter's five forces analysis
• FIG. 14 U.S. Retail Pharmacy de-identified health data market : PESTLE analysis
• FIG. 15 U.S. Retail Pharmacy de-identified health data market , Dataset Type Outlook Key Takeaways (USD million)
• FIG. 16 U.S. Retail Pharmacy de-identified health data market : Dataset Type Movement Analysis, 2024 & 2030 (USD Million)
• FIG. 17 Drug Supply Chain Security Data (DSCSA) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 18 Pharmaceutical Manufacturers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 19 Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 20 R&D Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 21 Drug Distributors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 22 Regulatory Tech Vendors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 23 Healthcare SaaS Vendors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 24 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 25 Market Basket Data Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 26 CPG & Pharma Brands Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 27 Marketing & AdTech Firms Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 28 Health Insurers & PBMs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 29 Retail Analytics Platforms Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 30 Others (Data Aggregators (e.g., NielsenIQ, IRI), etc.) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 31 Inventory Data Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 32 Pharma Manufacturers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 33 Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 34 R&D Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 35 Distributors/Wholesalers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 36 AI/ML Inventory Optimization Vendors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 37 Others (Clinical Supply Vendors, etc.) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 38 Prior Authorization Data Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 39 Payers & PBMs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 40 Pharma Market Access Teams Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 41 Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 42 R&D Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 43 Health IT Providers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 44 Consulting & Policy Firms Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 45 Others (Advocacy Groups, etc.) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 46 Episodic / Pharmacy Rx Claims Data Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 47 Value-based Payers & ACOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 48 Pharma Outcomes Teams Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 49 Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 50 R&D Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 51 Real-world Evidence Vendors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 52 Health IT Providers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 53 Others (AI/ML Healthtech Firms, etc.) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• FIG. 54 Company categorization
• FIG. 55 Strategic framework